Characterization of preclinical models of prostate cancer using PET-based molecular imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 8, 2009, Pages 1245-1255

  Belloli, Sara ^a,b,c   Jachetti, Elena ^a,e   Moresco, Rosa M ^a,b,c   Picchio, Maria ^a,b,c   Lecchi, Michela ^d   Valtorta, Silvia ^a,d   Freschi, Massimo ^a   Michelini, Rodrigo Hess ^a   Bellone, Matteo ^a   Fazio, Ferruccio ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

11C Choline; 18F FDG; PET; Prostate cancer; TRAMP mouse

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; CARBON; CHOLINE; DIAGNOSTIC AGENT; HORMONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MODEL; CONTROLLED STUDY; DISEASE COURSE; HISTOPATHOLOGY; IN VIVO STUDY; LONGITUDINAL STUDY; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE ADENOCARCINOMA; TRANSGENICS; ANIMAL; C57BL MOUSE; CANCER STAGING; CHEMISTRY; DISEASE MODEL; HUMAN; METABOLISM; PATHOLOGY; PROSTATE TUMOR; REPRODUCIBILITY; SCINTISCANNING; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CHOLINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; HORMONES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 70349231159     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1091-3     Document Type: Article

References (48)

1. RF Gittes 1991 Carcinoma of the prostate N Engl J Med 324 4 236 245 1985245 1:STN:280:DyaK3M%2Foslyqsw%3D%3D
2. DJ Margolis JM Hoffman RJ Herfkens RB Jeffrey A Quon SS Gambhir 2007 Molecular imaging techniques in body imaging Radiology 245 2 333 356 17940297 10.1148/radiol.2452061117 (Pubitemid 47612513)
3. N Lawrentschuk ID Davis DM Bolton AM Scott 2006 Positron emission tomography and molecular imaging of the prostate: an update BJU Int 97 5 923 931 16643472 10.1111/j.1464-410X.2006.06040.x 1:CAS:528:DC%2BD28XlsVCgtb0%3D
4. A Ramirez de Molina J Sarmentero-Estrada C Belda-Iniesta M Taron V Ramirez de Molina P Cejas, et al. 2007 Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study Lancet Oncol 8 10 889 897 17851129 10.1016/S1470-2045(07) 70279-6 1:CAS:528:DC%2BD2sXhtFektbzN (Pubitemid 47488053)
5. IJ de Jong J Pruim PH Elsinga W Vaalburg HJ Mensink 2003 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 1 32 38 12814672 10.1016/S0302-2838(03)00207-0 (Pubitemid 36741372)
6. M Picchio C Messa C Landoni L Gianolli S Sironi M Brioschi, et al. 2003 Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography J Urol 169 4 1337 1340 12629355 10.1097/01.ju.0000056901.95996.43 1:CAS:528:DC%2BD3sXhvFahs7o%3D (Pubitemid 36323779)
7. S Yoshida K Nakagomi S Goto M Futatsubashi T Torizuka 2005 11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging Urol Int 74 3 214 220 15812206 10.1159/000083551 1:CAS:528:DC%2BD2MXivFKjtb4%3D (Pubitemid 41201531)
8. DT Schmid H John R Zweifel T Cservenyak G Westera GW Goerres, et al. 2005 Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 2 623 628 15858102 10.1148/radiol.2352040494 (Pubitemid 40571106)
9. M Heinisch A Dirisamer W Loidl F Stoiber B Gruy S Haim, et al. 2006 Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml? Mol Imaging Biol 8 1 43 48 16315004 10.1007/s11307-005-0023-2 (Pubitemid 44193401)
10. V Scattoni M Picchio N Suardi C Messa M Freschi M Roscigno, et al. 2007 Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy Eur Urol 52 2 423 429 17397992 10.1016/j.eururo.2007.03.032 (Pubitemid 46963456)
11. DB Husarik R Miralbell M Dubs H John OT Giger A Gelet, et al. 2008 Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer Eur J Nucl Med Mol Imaging 35 2 253 263 17926036 10.1007/s00259-007-0552- 9
12. BJ Krause M Souvatzoglou M Tuncel K Herrmann AK Buck C Praus, et al. 2008 The detection rate of [(11)C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer Eur J Nucl Med Mol Imaging 35 1 18 23 17891394 10.1007/s00259-007-0581-4 1:CAS:528: DC%2BD2sXhsVSmtLbO (Pubitemid 350234152)
13. H Schoder SM Larson 2004 Positron emission tomography for prostate, bladder, and renal cancer Semin Nucl Med 34 4 274 292 15493005 10.1053/j.semnuclmed.2004.06.004 (Pubitemid 39365998)
14. T Hara 2002 11C-choline and 2-deoxy-2-[18F]fluoro-D-glucose in tumor imaging with positron emission tomography Mol Imaging Biol 4 4 267 273 14537115 10.1016/S1536-1632(02)00015-X (Pubitemid 35214587)
15. C Abate-Shen MM Shen 2002 Mouse models of prostate carcinogenesis Trends Genet 18 5 S1 S5 12047956 10.1016/S0168-9525(02)02683-5 1:CAS:528: DC%2BD38XjvFCgsbo%3D (Pubitemid 34607143)
16. CF Chiang EL Son GJ Wu 2005 Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis Prostate 64 4 408 418 15789364 10.1002/pros.20260 1:CAS:528:DC%2BD2MXhtVGmt77N (Pubitemid 41193254)
17. NM Greenberg F DeMayo MJ Finegold D Medina WD Tilley JO Aspinall, et al. 1995 Prostate cancer in a transgenic mouse Proc Natl Acad Sci U S A 92 8 3439 3443 7724580 10.1073/pnas.92.8.3439 1:CAS:528:DyaK2MXltFSmsr4%3D
18. PJ Kaplan-Lefko TM Chen MM Ittmann RJ Barrios GE Ayala WJ Huss, et al. 2003 Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model Prostate 55 3 219 237 12692788 10.1002/pros.10215 (Pubitemid 36532401)
19. G Han BA Foster S Mistry G Buchanan JM Harris WD Tilley, et al. 2001 Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer J Biol Chem 276 14 11204 11213 11063747 10.1074/jbc.M008207200 1:CAS:528:DC%2BD3MXjvFGjsLo%3D (Pubitemid 38089305)
20. WJ Huss CF Hanrahan RJ Barrios JW Simons NM Greenberg 2001 Angiogenesis and prostate cancer: identification of a molecular progression switch Cancer Res 61 6 2736 2743 11289156 1:CAS:528:DC%2BD3MXisVSksbo%3D
21. BA Narayanan NK Narayanan B Pittman BS Reddy 2004 Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model Clin Cancer Res 10 22 7727 7737 15570007 10.1158/1078-0432.CCR-04-0732 1:CAS:528:DC%2BD2cXhtVanur3L (Pubitemid 39557538)
22. PJ Kaplan S Mohan P Cohen BA Foster NM Greenberg 1999 The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model Cancer Res 59 9 2203 2209 10232609 1:CAS:528:DyaK1MXjtVWjtrk%3D
23. SB Shappell GV Thomas RL Roberts R Herbert MM Ittmann MA Rubin, et al. 2004 Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee Cancer Res 64 6 2270 2305 15026373 10.1158/0008-5472.CAN-03-0946 1:CAS:528:DC%2BD2cXitFCnsrs%3D (Pubitemid 38339483)
24. BA Foster JR Gingrich ED Kwon C Madias NM Greenberg 1997 Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model Cancer Res 57 16 3325 3330 9269988 1:CAS:528:DyaK2sXls1ShtLs%3D
25. WJ Huss DR Gray K Tavakoli ME Marmillion LE Durham MA Johnson, et al. 2007 Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model Neoplasia 9 11 938 950 18030362 10.1593/neo.07562 1:CAS:528:DC%2BD2sXhtl2rtrrM (Pubitemid 350086439)
26. N Vashchenko PA Abrahamsson 2005 Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities Eur Urol 47 2 147 155 15661408 10.1016/j.eururo.2004.09.007 1:CAS:528:DC%2BD2MXhslyht7w%3D (Pubitemid 40126970)
27. Hansson J, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Scand J Urol Nephrol Suppl. 2003;(212):28-36.
28. MH Ather F Abbas 2000 Prognostic significance of neuroendocrine differentiation in prostate cancer Eur Urol 38 5 535 542 11096233 10.1159/000020352 1:STN:280:DC%2BD3M7htVCrtQ%3D%3D
29. A Degrassi M Russo E Scanziani A Giusti R Ceruti G Texido, et al. 2007 Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials Prostate 67 4 396 404 17187397 10.1002/pros.20511 (Pubitemid 46341080)
30. E Degl'Innocenti M Grioni A Boni A Camporeale MT Bertilaccio M Freschi, et al. 2005 Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization Eur J Immunol 35 1 66 75 15597325 10.1002/eji.200425531 (Pubitemid 40123853)
31. T Hara N Kosaka H Kishi 1998 PET imaging of prostate cancer using carbon-11-choline J Nucl Med 39 6 990 995 9627331 1:CAS:528:DyaK1cXktV2itrg%3D
32. TA Smith RI Sharma AM Thompson FE Paulin 2006 Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro J Nucl Med 47 9 1525 1530 16954562 1:CAS:528:DC%2BD28XhtVCmtLfP
33. P Davoodpour M Bergström M Landström 2004 Effects of 2-methoxyestradiol on proliferation, apoptosis and PET-tracer uptake in human prostate cancer cell aggregates Nucl Med Biol 31 7 867 874 15464388 10.1016/j.nucmedbio.2004.03.015 1:CAS:528:DC%2BD2cXotFClsrw%3D (Pubitemid 39297684)
34. T Hara A Bansal TR DeGrado 2006 Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells Nucl Med Biol 33 8 977 984 17127170 10.1016/j.nucmedbio.2006.08.002 1:CAS:528:DC%2BD28Xht1Cls7%2FF (Pubitemid 44791951)
35. A Del Guerra N Belcari 2002 Advances in animal PET scanners Q J Nucl Med 46 1 35 47 12072844 1:STN:280:DC%2BD38zjtVSitg%3D%3D
36. A Motta C Damiani A Del Guerra G Di Domenico G Zavattini 2002 Use of a fast EM algorithm for 3D image reconstruction with the YAP-PET tomograph Comput Med Imaging Graph 26 5 293 302 12204233 10.1016/S0895-6111(02)00034-4 1:STN:280:DC%2BD38vkslOntA%3D%3D (Pubitemid 36151584)
37. MT Bertilaccio M Grioni BW Sutherland E Degl'Innocenti M Freschi E Jachetti, et al. 2008 Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer Prostate 68 10 1105 1115 18437689 10.1002/pros.20775 1:CAS:528:DC%2BD1cXovFOgsro%3D (Pubitemid 351875182)
38. N Oyama H Akino Y Suzuki H Kanamaru N Sadato Y Yonekura, et al. 1999 The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer Jpn J Clin Oncol 29 12 623 629 10721945 10.1093/jjco/29.12.623 1:STN:280:DC%2BD3c7osFShsg%3D%3D
39. N Oyama H Akino Y Suzuki H Kanamaru Y Miwa H Tsuka, et al. 2002 Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer Mol Imaging Biol 4 1 99 104 14538053 10.1016/S1095-0397(01)00065-6 (Pubitemid 34272714)
40. Y Zhang M Saylor S Wen MD Silva M Rolfe J Bolen, et al. 2006 Longitudinally quantitative 2-deoxy-2-[18F]fluoro-D-glucose micro positron emission tomography imaging for efficacy of new anticancer drugs: a case study with bortezomib in prostate cancer murine model Mol Imaging Biol 8 5 300 308 16897318 10.1007/s11307-006-0052-5 1:CAS:528:DC%2BD28XhtFOhs7nL (Pubitemid 44446024)
41. DT Price RE Coleman RP Liao CN Robertson TJ Polascik TR DeGrado 2002 Comparison of [18F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer J Urol 168 1 273 280 12050555 10.1016/S0022-5347(05)64906-3
42. AI Evangelou SF Winter WJ Huss RA Bok NM Greenberg 2004 Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype J Cell Biochem 91 4 671 683 14991759 10.1002/jcb.10771 1:CAS:528:DC%2BD2cXitlGis7g%3D
43. M Freschi R Colombo R Naspro P Rigatti 2004 Primary and pure neuroendocrine tumor of the prostate Eur Urol 45 2 166 169 14734001 10.1016/j.eururo.2003.08.014 (Pubitemid 38147822)
44. A Sciarra A Cardi C Dattilo G Mariotti F Di Monaco F Di Silverio 2006 New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma Int J Clin Pract 60 4 462 470 16620361 10.1111/j.1742-1241.2006. 00750.x 1:CAS:528:DC%2BD28Xltlehs7c%3D
45. S Shimizu J Kumagai Y Eishi T Uehara S Kawakami T Takizawa, et al. 2007 Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy Prostate 67 6 645 652 17342745 10.1002/pros.20493 (Pubitemid 46685285)
46. G Giovacchini M Picchio E Coradeschi V Scattoni V Bettinardi C Cozzarini, et al. 2008 [(11)C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy Eur J Nucl Med Mol Imaging 35 6 1065 1073 18200444 10.1007/s00259-008- 0716-2 1:CAS:528:DC%2BD1cXlvVClt78%3D
47. M Farsad R Schiavina P Castellucci C Nanni B Corti G Martorana, et al. 2005 Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis J Nucl Med 46 10 1642 1649 16204714 1:CAS:528:DC%2BD28XitVGlt74%3D
48. JR Gingrich RJ Barrios RA Morton BF Boyce FJ DeMayo MJ Finegold, et al. 1996 Metastatic prostate cancer in a transgenic mouse Cancer Res 56 18 4096 4102 8797572 1:CAS:528:DyaK28XlslGgsb4%3D